VEENENDAAL, The Netherlands, June 2 /PRNewswire/ -- Nucletron BV, the innovative cancer radiation solutions company, today announced the creation of an exclusive partnership and plan to merge with sector peer Isodose Control BV for an undisclosed sum. The two companies, headquartered in Veenendaal and Ede, the Netherlands, are complementary and the combination will strengthen Nucletron's position as global leader in the market for high-precision radiation therapy equipment and software, or brachytherapy.
The merger plans were announced by the two companies CEOs on Monday June 1 in Toronto, Canada, at the American Brachytherapy Society's annual conference.
"By combining strengths we will become the undisputed global market leader in brachytherapy, which offers quality, safe and effective treatment options for the most frequently occurring kinds of cancer," said Jos Lamers, CEO of Nucletron.
Nucletron is the world's number one medical equipment provider in the brachytherapy market, with a strong focus on customer support; Isodose Control has grown in six years to become number three and has an impressive product innovation track record.
"Isodose Control has developed a range of innovative brachytherapy products and has a promising range in development. Together with Nucletron, we look forward to speeding up the market introductions of these innovations to healthcare institutions and their patients worldwide," said Eric van't Hooft, CEO of Isodose Control BV.
Van 't Hooft in fact founded Nucletron in 1975 and built it into a
successful technology company, before merging it to Dutch stock
exchange-listed Delft Instruments NV in 1994. Van 't Hooft left nine years
later to found Isodose Control in 2003. Van't Hooft, who was awarded a
knighthood and the title Commander in the order of the Dutch Lion for his
services to science, will become a member of the Executive Manag
|SOURCE Nucletron B V|
Copyright©2009 PR Newswire.
All rights reserved